New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma

Journal of Clinical Pathology

Volumn 62, Issue 11, 2009, Pages 986-997

  Adams, H ^a   Tzankov, A ^a   Lugli, A ^a   Zlobec, I ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; KI 67 ANTIGEN; MAMMALIAN STERILE LIKE 20 KINASE 1; MUCIN 2; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; COLON CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 73349109499     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.059063     Document Type: Article

References (43)

1. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-34.
2. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
4. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, et al. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999;86:1421-30.
5. Sturm I, Kohne CH, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-74.
6. Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006;13:823- 35.
7. Resnick MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004;10:3069-75.
8. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102-8.
9. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901.
10. Zlobec I, Terracciano L, Jass JR, et al. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 2007;451:763-9.
11. Zlobec I, Steele R, Michel RP, et al. Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol 2006;19:1236-42.
12. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071-8.
13. Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology 2003;229:3-8.
14. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007;115:654-7.
15. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007;60:1112-16.
16. Brunner A, Prelog M, Verdorfer I, et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinomas of the bladder. J Clin Pathol 2008;61:307-10.
17. Obermann EC, Went P, Zimpfer A, et al. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large Bcell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer 2005;5:162.
18. Salinas-Sanchez AS, Atienzar-Tobarra M, Lorenzo-Romero JG, et al. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma. Urol Int 2007;79:321-7.
19. Zlobec I, Minoo P, Baumhoer D, et al. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2007;112:495-502.
20. Soreide K, Gudlaugsson E, Skaland I, et al. Metachronous cancer development in patients with sporadic colorectal adenomas-multivariate risk model with independent and combined value of hTERT and survivin. Int J Colorectal Dis 2008;23:389-400.
21. Shlipak MG, Ix JH, Bibbins-Domingo K, et al. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008;121:50-7.
22. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9.
23. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44.
24. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. JAMA 2007;99:526-32.
25. Guo L, Ma Y, Ward R, et al. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 2006;12:3344-54.
26. Ma Y, Qian Y, Wei L, et al. Population-based molecular prognosis of breast cancer by transcriptional profiling. Clin Cancer Res 2007;13:2014-22.
27. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discovery 2003;2:962-72.
28. Tzankov A, Gschwendtner A, Augustin F, et al. Diffuse large B-cell lymphoma with overexpression of cyclin E substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006;12:2125-32.
29. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
30. Vogelstein B. Cancer. A deadly inheritance. Nature 1990;348:681-2.
31. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434- 44.
32. Lee KK, Ohyama T, Yajima N, et al. MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J Biol Chem 2001;276:19276-85.
33. Minoo P, Zlobec I, Baker K, et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 2007;20:331-8.
34. Ajioka Y, Watanabe H, Jass JR. MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J Clin Pathol 1997;50:417-21.
35. Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122-36
36. Seetoo DQ, Crowe PJ, Russell PJ, et al. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003;82:184-93.
37. Yang JL, Seetoo D, Wang Y, et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 2000;89:431-9.
38. Brown PJ, Ashe SL, Leich E, et al. Potentially oncogenic B-cell activation induced smaller isoforms of FOXP1 are highly expressed in the activated B-cell-like subtype of DLBCL. Blood 2008;111:2816-24.
39. Fenton JA, Schuuring E, Barrans SL, et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2006;45:164-8.
40. Haralambieva E, Adam P, Ventura R, et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 2006;20:1300-3.
41. Wlodarska I, Veyt E, De Paepe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005;19:1299-305.
42. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005;11:1065-72.
43. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933-5.